Misplaced Pages

Latest revision as of 02:35, 27 September 2024

This article needs more reliable medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. Find sources: "Natalizumab" – news · newspapers · books · scholar · JSTOR (November 2018)

Natalizumab

Natalizumab Fab fragment bound to the headpiece of an α4-integrin. From PDB 4IRZ​.
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	alpha-4 integrin
Clinical data
Trade names	Tysabri, others
Other names	AN100226M, Antegren
Biosimilars	natalizumab-sztn, Tyruko
AHFS/Drugs.com	Monograph
MedlinePlus	a605006
License data	US DailyMed: Natalizumab
Pregnancy category	AU: C
Routes of administration	Intravenous
ATC code	L04AG03 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only Schedule D UK: POM (Prescription only) US: WARNINGRx-only EU: Rx-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	n/a
Elimination half-life	11 ± 4 days
Identifiers
CAS Number	189261-10-7
DrugBank	DB00108
ChemSpider	none
UNII	3JB47N2Q2P
KEGG	D06886
ChEMBL	ChEMBL1201607
CompTox Dashboard (EPA)	DTXSID90920506
Chemical and physical data
Molar mass	149 kg/mol
(what is this?)  (verify)

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier.

Natalizumab, is a monoclonal antibody which targets a protein called α4β1 integrin on white blood cells involved in inflammation. By attaching to integrin, natalizumab is thought to stop white blood cells from entering the brain and spinal cord tissue, thereby reducing inflammation and the resulting nerve damage.

The most common side effects are urinary tract infection, nasopharyngitis (inflammation of the nose and throat), headache, dizziness, nausea, joint pain and tiredness.

Natalizumab was approved for medical use in the United States in 2004. It was subsequently withdrawn from the market by its manufacturer after it was linked with three cases of the rare neurological condition progressive multifocal leukoencephalopathy (PML) when administered in combination with interferon beta-1a, another immunosuppressive drug often used in the treatment of multiple sclerosis. After a review of safety information and no further deaths, the drug was returned to the US market in 2006 under a special prescription program. As of June 2009, ten cases of PML were known. However, twenty-four cases of PML had been reported since its reintroduction by October 2009, showing a sharp rise in the number of fatalities and prompting a review of the chemical for human use by the European Medicines Agency. By 2010, 31 cases of PML were attributed to natalizumab while by 2018 this had risen to 757 cases. The US Food and Drug Administration (FDA) did not withdraw the drug from the market as benefits outweigh the risks. In the European Union, it has been approved only for multiple sclerosis and only by itself as the initial cases of PML, and later the fatalities, were said by the manufacturers to be linked to the use of previous medicines by the person.

Medical uses

In the United states, natalizumab is indicated for the treatment of multiple sclerosis and Crohn's disease. It is indicated to treat clinically isolated syndrome – a single, first occurrence of multiple sclerosis symptoms; relapsing-remitting disease – a type of multiple sclerosis that occurs when people have episodes of new neurological symptoms followed by periods of stability; and active secondary progressive disease – when, following a relapsing-remitting course, patients experience gradual disability worsening with continued relapses.

Natalizumab offers a limited improvement in efficacy compared to other treatments for multiple sclerosis, but due to the lack of information about long-term use, as well as potentially fatal adverse events, reservations have been expressed over the use of the drug outside of comparative research with existing medications. Natalizumab is used as a monotherapy.

In the European Union, natalizumab is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:

• People with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT), or
• People with rapidly evolving severe relapsing remitting multiple sclerosis defined by two or more disabling relapses in one year, and with one or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

Adverse effects

The US prescribing information for natalizumab contains a boxed warning about the increased risk of progressive multifocal leukoencephalopathy, a viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of progressive multifocal leukoencephalopathy include the presence of anti-JCV antibodies (antibodies to the JC virus, a typically harmless virus carried by most humans), longer duration of therapy and prior use of immunosuppressants.

It was first observed in seven patients who received natalizumab in late 2008; three cases were noted in clinical trials in 2006 leading to the drug being temporarily pulled from the market; two cases were reported to the FDA in August 2008; and two cases were announced in December 2008. By January 2010, the FDA noted a total of 31 confirmed cases of PML, with the chance of developing the infection increasing as the number of infusions received by a patient increased. Because of this association, the drug label and package insert accompanying the drug will be updated to include this information. As of February 2012, there were 212 confirmed cases of PML among 99,571 patients treated with natalizumab (2.1 cases per 1000 patients). All 54 patients with PML for whom samples were available before the diagnosis were positive for anti–JC virus antibodies. When the risk of PML was evaluated according to three risk factors, it was lowest among the patients who had used natalizumab for the shortest periods, those who had used few if any immunosuppressant drugs to treat MS in the past, and lastly who were negative for anti–JC virus antibodies. The incidence of PML in the low risk group was estimated to be 0.09 cases, or less, per 1000 patients. Patients who had taken natalizumab for longer, from 25 to 48 months, who were positive for anti–JC virus antibodies, had taken immunosuppressants before the initiation of natalizumab therapy had the highest risk of developing PML. Their risk is fully 123 times higher than the low risk group. (incidence, 11.1 cases per 1000 patients ). While none of them had taken the drug in combination with other disease-modifying treatments, previous use of MS treatments increases the risk of PML between 3 and 4-fold. In 2016, EMA recommended all people taking natalizumab should undergo full MRI scans at least once a year due to concerns of progressive multifocal leukoencephalopathy (PML). In addition, more frequent MRI scans (e.g. every 3 to 6 months) should be performed using simplified protocols should be considered for those at higher risk of PML.

Postmarketing surveillance in early 2008 revealed that 0.1% of people taking natalizumab experience clinically significant liver injury, leading to the FDA, EMEA and manufacturers recommending that the medication be discontinued in patients with jaundice or other evidence of significant liver damage. This rate is comparable to other immune-suppressing drugs. Evidence of hepatotoxicity in the form of elevated blood levels of bilirubin and liver enzymes can appear as soon as six days after an initial dose; reactions are unpredictable and may appear even if the patient does not react to previous treatment. Such signs reoccur upon rechallenge in some patients, indicating that damage is not coincidental. In the absence of any blockage these liver function tests are predictors of severe liver injury with possible sequelae of liver transplantation or death.

Common adverse effects include fatigue and allergic reactions with a low risk of anaphylaxis, headache, nausea, colds and exacerbation of Crohn's disease in a minority of patients with the condition. Adolescents with Crohn's disease experience headache, fever and exacerbation of Crohn's disease.

About 6% of the people in studies developed long-lasting antibodies against natalizumab, which reduced the medicine's effectiveness.

Mechanism of action

Natalizumab is a humanized monoclonal antibody against alpha-4 (α4) integrin, the first drug developed in the class of selective adhesion molecule inhibitors. α4-integrin is required for white blood cells to move into organs, and natalizumab's mechanism of action is believed to be the prevention of immune cells from crossing blood vessel walls to reach affected organs.

Multiple sclerosis

The symptom-causing lesions of MS are believed to be caused when inflammatory cells such as T-lymphocytes pass through the blood–brain barrier through interaction with receptors on the endothelial cells. Natalizumab appears to reduce the transmission of immune cells into the central nervous system by interfering with the α4β7-integrin receptor molecules on the surfaces of cells. The effect appears to occur on endothelial cells expressing the VCAM-1 gene, and in parenchymal cells expressing the osteopontin gene. In animals used to model MS and test therapies, repeated administration of natalizumab reduced migration of leukocytes into the brain's parenchyma, and also reduced lesioning, though it is uncertain if this is clinically significant for humans.

Individuals with MS dosed with natalizumab demonstrated increased CD34-expressing cells, with research suggesting a peak in expression after 72 hours.

Crohn's disease

The interaction of the α4β7 integrin and the addressin (also known as MADCAM1) endothelial cell receptor is believed to contribute to the chronic bowel inflammation that causes Crohn's disease. Addressin is primarily expressed in the endothelium of venules in the small intestine and are critical in guiding T-lymphocytes to lymphatic tissues in Peyer's patches. In CD patients, sites of active inflammation of the bowel in CD patients have increased expression of addressin, suggesting a connection between the inflammation and the receptor. Natalizumab may block interaction between the α4β7 integrin and addressin at sites of inflammation. Animal models have found higher levels of VCAM-1 expression in mice with irritable bowel syndrome and the VCAM-1 gene may also play a part in CD but its role is not yet clear.

Interactions

Natalizumab appears to interact with other immune-modulating drugs to increase the risk of progressive multifocal leukoencephalopathy (PML), an often-fatal opportunistic infection caused by the JC virus. In 2005, two people taking natalizumab in combination with interferon beta-1a developed PML. One died, and the other recovered with disabling sequelae. A third fatal case initially attributed to an astrocytoma was reported in a patient being treated for Crohn's disease. Though the patient was being treated with natalizumab in combination with azathioprine, corticosteroids and infliximab, indications of PML infection appeared only after natalizumab monotherapy was re-introduced. No deaths from progressive multifocal leukoencephalopathy have been linked to natalizumab when it was not combined with other immune-modulating drugs and other rates of opportunistic infections are not increased in patients taking natalizumab possibly due to the drug's mechanism of action. Other than a prior history of PML, there is no known method to identify patients at risk of developing PML. Natalizumab's label indicates that it is contraindicated for immunosuppressed individuals or those with a history of PML. Due to the uncertain risk of PML, natalizumab is only available through a restricted distribution program. By January 2010, the United States Food and Drug Administration reported a total of 31 confirmed cases of PML associated with natalizumab.

Though the small number of cases precludes conclusion on the ability of natalizumab alone to induce PML, its black box warning states that the drug has only been linked to PML when combined with other immune-modulating drugs and natalizumab is contraindicated for use with other immunomodulators. Corticosteroids may produce immunosuppression, and the Tysabri prescribing information recommends that people taking corticosteroids for the treatment of Crohn's disease have their doses reduced before starting natalizumab treatment. The risk of developing PML was later estimated to be 1 in 1,000 (0.1%) over 18 months though the longer term risks of PML are unknown.

History

Biogen Idec announced the initiation of the first clinical trial of natalizumab as a potential cancer treatment as of September 2008.

Society and culture

Legal status

Natalizumab was originally approved for treatment of multiple sclerosis in 2004, through the FDA's accelerated Fast Track program, due to the drug's efficacy in one-year clinical trials. In February 2005, four months after its approval, natalizumab was withdrawn voluntarily by the manufacturer after two cases of progressive multifocal leukoencephalopathy. Groups representing individuals with MS lobbied to have the drug returned to the US market and in June 2006, after recommendation by an advisory committee and a review of two years of safety and efficacy data, the FDA re-approved natalizumab for patients with all relapsing forms of MS (relapse-remitting, secondary-progressive, and progressive-relapsing) as a first-line or second-line therapy. Patients taking natalizumab must enter into a registry for monitoring. Natalizumab is the only drug after alosetron withdrawn for safety reasons that returned to the US market.

In April 2006, the Committee for Medicinal Products for Human Use recommended authorizing natalizumab to treat relapsing-remitting MS, and natalizumab was approved for medical use in the European Union in June 2006.

Health Canada added natalizumab to Schedule F of the Food and Drug Regulations in April 2008, as a prescription drug requiring oversight from a physician.

In 2007, the EMA rejected the application to market natalizumab for Crohn's disease due to concerns over its risk/benefit ratio. In January 2008, the FDA approved it for the induction of remission and maintenance of remission for moderate to severe Crohn's disease.

Biosimilars

In July 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tyruko, intended for the treatment of multiple sclerosis. The applicant for this medicinal product is Sandoz GmbH. Tyruko was approved for medical use in the European Union in September 2023.

In August 2023, the FDA approved approved Tyruko (natalizumab-sztn) and granted approval to Sandoz Inc.

References

1. ^ "Tyruko (natalizumab-sztn) injection, for intravenous use" (PDF). Archived (PDF) from the original on 25 August 2023. Retrieved 25 August 2023.
2. ^ "Tyruko EPAR". European Medicines Agency. 28 September 2023. Archived from the original on 28 October 2023. Retrieved 6 October 2023.
3. "Natalizumab (Tysabri) Use During Pregnancy". Drugs.com. 24 September 2019. Archived from the original on 23 November 2020. Retrieved 4 May 2020.
4. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
5. "Tysabri natalizumab 150 mg/1 mL injection solution pre-filled syringe (353845)". Therapeutic Goods Administration (TGA). 12 August 2022. Archived from the original on 25 August 2023. Retrieved 25 August 2023.
6. "Tysabri Product and Consumer Medicine Information Licence". TGA eBS. Archived from the original on 3 July 2022. Retrieved 25 August 2023.
7. "Tysabri Product information". Health Canada. 22 October 2009. Archived from the original on 25 August 2023. Retrieved 25 August 2023.
8. "Tysabri 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 14 November 2019. Archived from the original on 22 October 2020. Retrieved 4 May 2020.
9. ^ "Tysabri- natalizumab injection". DailyMed. 12 August 2019. Archived from the original on 27 March 2020. Retrieved 4 May 2020.
10. ^ "Tysabri EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 August 2020. Retrieved 4 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
11. "Meeting highlights from the Committee for Medicinal Products for Human Use" (PDF). European Medicines Agency. 22 October 2009. Archived from the original (PDF) on 27 December 2009. Retrieved 31 August 2010.
12. ^ Jeffrey S (5 February 2010). "PML Risk Increases With Repeated Natalizumab Infusions: FDA". Medscape. Archived from the original on 26 January 2012. Retrieved 31 August 2010.
13. "Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time". ECTRIMS. 10 October 2018. Archived from the original on 28 October 2021. Retrieved 18 July 2019.
14. Hitti M (1 August 2008). "MS Drug Tysabri Tied to Brain Infection". WebMD. Archived from the original on 20 November 2018. Retrieved 31 August 2010.
15. Staton T (26 October 2009). "Tysabri safety falls under EMEA scrutiny". Fierce Pharma. Archived from the original on 23 January 2021. Retrieved 20 November 2018.
16. ^ "FDA Approves First Biosimilar to Treat Multiple Sclerosis". U.S. Food and Drug Administration (FDA) (Press release). 24 August 2023. Archived from the original on 25 August 2023. Retrieved 25 August 2023. This article incorporates text from this source, which is in the public domain.
17. "Natalizumab: new drug. Multiple sclerosis: risky market approval". Prescrire International. 17 (93): 7–10. February 2008. PMID 18354844.
18. ^ Hutchinson M (June 2007). "Natalizumab: A new treatment for relapsing remitting multiple sclerosis". Therapeutics and Clinical Risk Management. 3 (2): 259–268. doi:10.2147/tcrm.2007.3.2.259. PMC 1936307. PMID 18360634.
19. Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, et al. (October 2011). "Natalizumab for relapsing remitting multiple sclerosis". The Cochrane Database of Systematic Reviews (10): CD007621. doi:10.1002/14651858.CD007621.pub2. PMID 21975773.
20. "Annex: Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the member states" (PDF). European Medicines Agency. Archived from the original (PDF) on 20 August 2007. Retrieved 9 March 2008.
21. ^ Greene RT (15 December 2008). "Biogen, Elan Report Brain Illness in Tysabri Patient". Bloomberg.com. Retrieved 21 December 2008.
22. ^ Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. (July 2005). "Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease". The New England Journal of Medicine. 353 (4): 362–368. doi:10.1056/NEJMoa051586. PMID 15947080.
23. U.S. Food and Drug Administration (August 2008). "Natalizumab Injection for Intraveneous {{sic}} Use (marketed as Tysabri)". U.S. Food and Drug Administration (FDA). Archived from the original on 19 December 2008. Retrieved 22 December 2008.
24. "FDA Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabri (natalizumab)". FDA. 2 May 2010. Archived from the original on 24 April 2019. Retrieved 31 August 2010.
25. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. (May 2012). "Risk of natalizumab-associated progressive multifocal leukoencephalopathy". The New England Journal of Medicine. 366 (20): 1870–1880. doi:10.1056/NEJMoa1107829. PMID 22591293.
26. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. (August 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring". Lancet Neurology. 10 (8): 745–58. doi:10.1016/S1474-4422(11)70149-1. PMID 21777829. S2CID 15639613.
27. "EMA confirms recommendations to minimise risk of brain infection PML with Tysabri". European Medicines Agency. 25 April 2016. Archived from the original on 23 January 2021. Retrieved 29 November 2019.
28. "FDA MedWatch - 2008 Safety Information Alerts". U.S. Food and Drug Administration (FDA). 28 February 2008. Archived from the original on 25 May 2009. Retrieved 5 April 2008.
29. "EMEA concludes new advice to doctors and patients for Tysabri (natalizumab) needed" (PDF). European Medicines Agency. 20 March 2008. Retrieved 5 April 2008.
30. "Questions and answers on Tysabri and liver injury" (PDF). European Medicines Agency. 20 March 2008. Retrieved 14 April 2008. ; lay-summary Archived 11 June 2008 at the Wayback Machine, second summary Archived 5 December 2008 at the Wayback Machine
31. Gross K (3 March 2008). "Multiple Sclerosis - Natalizumab (Tysabri) Can Rarely Cause Liver Problems". Archived from the original on 7 November 2016. Retrieved 5 April 2008.
32. ^ Panzara M, Francis V (1 February 2008). "Important safety information: Dear Healthcare Practitioner letter" (PDF). Biogen Idec and Élan. Archived (PDF) from the original on 12 May 2009. Retrieved 11 April 2008.; lay summary Archived 11 June 2008 at the Wayback Machine
33. Horga A, Horga de la Parte JF (2007). "". Rev Neurol (in Spanish). 45 (5): 293–303. PMID 17876741.
34. Rice GP, Hartung HP, Calabresi PA (2005). "Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale". Neurology. 64 (8): 1336–42. doi:10.1212/01.WNL.0000158329.30470.D0. PMID 15851719. S2CID 39916466.
35. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R (2008). "The monoclonal anti-VLA4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans". Blood. 111 (7): 3893–5. doi:10.1182/blood-2007-10-120329. PMID 18235044. S2CID 206866717.
36. Kleinschmidt-DeMasters BK, Tyler KL (July 2005). "Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis". The New England Journal of Medicine. 353 (4): 369–374. doi:10.1056/NEJMoa051782. PMID 15947079.
37. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (July 2005). "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab". The New England Journal of Medicine. 353 (4): 375–381. doi:10.1056/NEJMoa051847. PMID 15947078.
38. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, et al. (March 2006). "Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy". The New England Journal of Medicine. 354 (9): 924–933. doi:10.1056/NEJMoa054693. PMC 1934511. PMID 16510746.
39. ^ Berger JR (October 2006). "Natalizumab". Drugs of Today. 42 (10): 639–655. doi:10.1358/dot.2006.42.10.1042190. PMID 17136224.
40. Ransohoff RM (August 2007). ""Thinking without thinking" about natalizumab and PML". Journal of the Neurological Sciences. 259 (1–2): 50–52. doi:10.1016/j.jns.2006.04.011. PMID 17521672. S2CID 28808262.
41. Aksamit AJ (November 2006). "Review of progressive multifocal leukoencephalopathy and natalizumab". The Neurologist. 12 (6): 293–298. doi:10.1097/01.nrl.0000250948.04681.96. PMID 17122725. S2CID 25003597.
42. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. (May 2007). "Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring". The Lancet. Neurology. 6 (5): 431–441. doi:10.1016/S1474-4422(07)70078-9. PMID 17434098. S2CID 18131415.
43. "Biogen Idec testing Tysabri as a cancer treatment". The Boston Globe. 5 September 2008. Archived from the original on 29 October 2013. Retrieved 5 September 2008.
44. ^ Pollack (9 March 2006). "F.D.A. Panel Recommends M.S. Drug Despite Lethal Risk". The New York Times. Archived from the original on 11 January 2016. Retrieved 13 March 2008.
45. "Errata to FDA Background document for the Tysabri (natalizumab) Advisory Committee on July 31, 2007" (PDF). U.S. Food and Drug Administration (FDA). 20 July 2007. Archived (PDF) from the original on 17 May 2017. Retrieved 9 March 2008.
46. Fiore D (2007). "Multiple sclerosis and Natalizumab". American Journal of Therapeutics. 14 (6): 555–560. doi:10.1097/MJT.0b013e31804bfa6a. PMID 18090880. S2CID 22339176.
47. "European Medicines Agency: Committee for Medicinal Products for Human Use 24–27 April 2006" (PDF) (Press release). European Medicines Agency (EMA). 28 April 2006. Archived (PDF) from the original on 10 July 2007. Retrieved 2 April 2008.
48. "SOR/2008-101: Food and Drug Act; Regulations Amending the Food and Drug Regulations (1528—Schedule F)" (PDF). Canada Gazette Part I. 142 (8): 649. 16 April 2008. Archived (PDF) from the original on 18 August 2011. Retrieved 18 December 2010.
49. "Refusal CHMP assessment report for natalizumab" (PDF). European Medicines Agency. 15 November 2007. Retrieved 2 April 2008. "lay-summary" (PDF). Archived (PDF) from the original on 18 July 2009. Retrieved 4 April 2008. (78.5 KB)
50. "FDA Approves Tysabri to Treat Moderate-to-Severe Crohn's Disease". U.S. Food and Drug Administration (FDA). 14 January 2008. Archived from the original on 23 May 2009. Retrieved 9 March 2008.
51. ^ "Tyruko: Pending EC decision". European Medicines Agency (EMA). 21 July 2023. Archived from the original on 25 August 2023. Retrieved 25 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
52. "Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar". PMLive. 24 July 2023. Archived from the original on 24 July 2023. Retrieved 24 July 2023.
53. "Biosimilar Drug Information". U.S. Food and Drug Administration (FDA). 1 November 2023. Archived from the original on 28 August 2021. Retrieved 26 November 2023.

Further reading

• Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, et al. (April 2017). "Natalizumab in Multiple Sclerosis: Long-Term Management". Int J Mol Sci. 18 (5): 940. doi:10.3390/ijms18050940. PMC 5454853. PMID 28468254.

• Medicine

• Monoclonal antibodies
• Immunosuppressants
• Withdrawn drugs